Liquidia Corp (LQDA) Latest Company News

Oct 14, 2026, 17:16 UTC
Liquidia Corp shares surged 25% to $33.47.
Source:
- proactiveinvestors.com
Oct 14, 2026, 14:00 UTC
Liquidia agreed to terminate its promotional agreement for treprostinil injection and stop supporting sales of the product in the market.
Source:
- s.kabutan.jp
Oct 14, 2026, 12:27 UTC
Liquidia Corp shares rose 41.51% to $37.94 in after-hours trading.
Source:
- s.kabutan.jp
- finance.sina.cn
Oct 14, 2026, 10:13 UTC
Liquidia Corp amended its Revenue Interest Financing Agreement, with Healthcare Royalty Partners LP consenting to a letter of credit from a third-party lender and the minimum cash covenant increasing from $15.0 million to $45.0 million.
Oct 13, 2026, 21:44 UTC
Liquidia Corp entered into a global settlement agreement with UNITED THERAPEUTICS Corp, resolving all pending litigation between the companies.
Source:
Oct 1, 2026, 17:20 UTC
United Therapeutics prevailed in its patent dispute with Liquidia over the Yutrepia product, a ruling that could limit Yutrepia's use in PH-ILD and reduce competition for United Therapeutics' Tyvaso products.
Source:
- zacks.com
- zacks.com
Sep 30, 2026, 17:20 UTC
The U.S. District Court for the District of Delaware ruled that two of the six patent claims asserted by United Therapeutics against Liquidia are valid and infringed, and directed the parties to submit a proposed form of judgment within one week.
Source:
Sep 10, 2026, 18:40 UTC
The FDA granted Fast Track designation to Liquidia's Yutrepia for the treatment of Raynaud's phenomenon associated with systemic sclerosis.
Source:
- zacks.com
Aug 20, 2026, 22:47 UTC
On August 20, 2026, Liquidia Corp's shares fell 5.8% to $71.05, continuing a decline from its 52-week high of $93.61.
Source:
- gurufocus.com
Aug 13, 2026, 05:02 UTC
Liquidia's YUTREPIA commercial launch continues to scale, with Q2 product sales of $170.4 million, up 31% sequentially.
Source:
- seekingalpha.com
Aug 12, 2026, 10:30 UTC
Liquidia Corporation reported second quarter 2026 financial results, with YUTREPIA net product sales of approximately $170.4 million, net income of $74.7 million, and adjusted EBITDA of $96.3 million.
Source:

LQDA

Liquidia Corp shares surged 25% to $33.47.

Liquidia agreed to terminate its promotional agreement for treprostinil injection and stop supporting sales of the product in the market.

Liquidia Corp shares rose 41.51% to $37.94 in after-hours trading.

Liquidia Corp amended its Revenue Interest Financing Agreement, with Healthcare Royalty Partners LP consenting to a letter of credit from a third-party lender and the minimum cash covenant increasing from $15.0 million to $45.0 million.

Liquidia Corp entered into a global settlement agreement with UNITED THERAPEUTICS Corp, resolving all pending litigation between the companies.

United Therapeutics prevailed in its patent dispute with Liquidia over the Yutrepia product, a ruling that could limit Yutrepia's use in PH-ILD and reduce competition for United Therapeutics' Tyvaso products.

The U.S. District Court for the District of Delaware ruled that two of the six patent claims asserted by United Therapeutics against Liquidia are valid and infringed, and directed the parties to submit a proposed form of judgment within one week.

The FDA granted Fast Track designation to Liquidia's Yutrepia for the treatment of Raynaud's phenomenon associated with systemic sclerosis.

On August 20, 2026, Liquidia Corp's shares fell 5.8% to $71.05, continuing a decline from its 52-week high of $93.61.

Liquidia's YUTREPIA commercial launch continues to scale, with Q2 product sales of $170.4 million, up 31% sequentially.

Liquidia Corporation reported second quarter 2026 financial results, with YUTREPIA net product sales of approximately $170.4 million, net income of $74.7 million, and adjusted EBITDA of $96.3 million.